Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells

2.50
Hdl Handle:
http://hdl.handle.net/2436/620217
Title:
Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
Authors:
Wang, Zhipeng; Tan, Jiao; McConville, Christopher; Kannappan, Vinodh; Tawari, Patricia Erebi; Brown, James; Ding, Jin; Armesilla, Angel L.; Irache, Juan M.; Mei, Qi-Bing; Tan, Yuhuan; Liu, Ying; Jiang, Wenguo; Bian, Xiuwu; Wang, Weiguang
Abstract:
Disulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hin serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.
Citation:
Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells 2016 Nanomedicine: Nanotechnology, Biology and Medicine
Publisher:
Elsevier
Journal:
Nanomedicine: Nanotechnology, Biology and Medicine
Issue Date:
Aug-2016
URI:
http://hdl.handle.net/2436/620217
DOI:
10.1016/j.nano.2016.08.001
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S1549963416301083
Type:
Article
Language:
en
ISSN:
15499634
Appears in Collections:
Molecular Pharmacology Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Zhipengen
dc.contributor.authorTan, Jiaoen
dc.contributor.authorMcConville, Christopheren
dc.contributor.authorKannappan, Vinodhen
dc.contributor.authorTawari, Patricia Erebien
dc.contributor.authorBrown, Jamesen
dc.contributor.authorDing, Jinen
dc.contributor.authorArmesilla, Angel L.en
dc.contributor.authorIrache, Juan M.en
dc.contributor.authorMei, Qi-Bingen
dc.contributor.authorTan, Yuhuanen
dc.contributor.authorLiu, Yingen
dc.contributor.authorJiang, Wenguoen
dc.contributor.authorBian, Xiuwuen
dc.contributor.authorWang, Weiguangen
dc.date.accessioned2016-10-17T15:34:02Z-
dc.date.available2016-10-17T15:34:02Z-
dc.date.issued2016-08-
dc.identifier.citationPoly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells 2016 Nanomedicine: Nanotechnology, Biology and Medicineen
dc.identifier.issn15499634-
dc.identifier.doi10.1016/j.nano.2016.08.001-
dc.identifier.urihttp://hdl.handle.net/2436/620217-
dc.description.abstractDisulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hin serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S1549963416301083en
dc.rightsArchived with thanks to Nanomedicine: Nanotechnology, Biology and Medicineen
dc.subjectDrug deliveryen
dc.subjectNano-technologyen
dc.subjectDrug repositioningen
dc.subjectCancer stem cellsen
dc.subjectLiver canceren
dc.subjectPLGAen
dc.subjectDisulfiramen
dc.titlePoly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cellsen
dc.typeArticleen
dc.identifier.journalNanomedicine: Nanotechnology, Biology and Medicineen
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.